Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 10.34% |
| SCIENTIFIC L | SCIL | 8.00% |
| OLD SECOND B | OSBC | 6.16% |
| A M R CP | AAMRQ | 5.27% |
| MAXWELL TECH | MXWL | 4.53% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Health Care REIT, Inc. ( HCN - Analyst Report ) recently announced that it has priced its underwritten public offering of 18 million shares at $53.50 per share with the total amount estimated at $963 million. In a bid to cover over-allotments, the company will provide a 30-day option to the underwriters for purchasing an additional 2.7 million shares.
HCN intends to utilize the proceeds generated from the transaction to repayadvances under its unsecured lines of credit, to repay other outstanding debts and for other general corporate purposes, including investing in health care and seniors housing properties.
This public offering will enable the company to attain financial flexibility and seize investment opportunities and acquisitions, which go a long way in enhancing top-line growth. As of December 31, 2011, HCN’s cash position stood at $163.5 million.
Health Care REIT reported fourth quarter 2011 FFO (funds from operations) of $154.4 million or 83 cents per share, compared with $85.1 million or 61 cents in the year-earlier quarter. Funds from operations, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
HCN is a real estate investment trust (REIT) that invests across the full spectrum of senior housing and health care real estate properties. Headquartered in Toledo, Ohio, Health Care REIT also provides an extensive array of property management and development services.
Health Care usually has long-term triple-net leases in senior housing and healthcare real estate properties that insulates it from market volatility and provides a steady source of revenue despite a challenging macroeconomic environment.
Health Care currently retains a Zacks #2 Rank, which translates into a short-term Buy rating. We are also maintaining our long-term Neutral recommendation on the stock. One of its competitors, HCP Inc. ( HCP - Analyst Report ) , currently has a Zacks #3 Rank, which translates into a short-term Hold rating.
Read the full Analyst Report on HCN
Read the full Analyst Report on HCP